Targeting the NLRP3 Inflammasome in Atherosclerosis: Advances in Anti‐Inflammatory Therapies With Bioactive Natural Products
Phytotherapy Research · 2026-05 · 40 (5) · 2758-2789
DOI: 10.1002/ptr.70260 ↗At a glance
Übersichtsarbeit in Phytotherapy Research, published online on 2026-02-27. Written by Haizhen Guo and 6 co-authors. Institution: Tianjin University of Traditional Chinese Medicine, Tianjin, China. Major MEDLINE topics: NLR Family, Pyrin Domain-Containing 3 Protein, Atherosclerosis, Inflammasomes, Anti-Inflammatory Agents. Cited 4 times so far (Crossref); 193 references. Funded by: The Science & Technology Development Fund of Tianjin Education Commission for Higher Education.
Abstract (original language)
Atherosclerosis (AS) serves as the shared pathological substrate for cardiovascular and cerebrovascular diseases. The traditional passive‐accumulation model centered on cholesterol no longer explains why lipid targets are met while clinical events persist and has therefore prompted a shift toward a combined anti‐inflammatory and lipid‐lowering strategy. Inflammasomes—particularly the NOD‐like receptor family pyrin domain‐containing 3 (NLRP3) inflammasome—integrate and amplify multiple pro‐atherogenic signals and have emerged as a key target. However, no agent targeting NLRP3 has yet gained Food and Drug Administration (FDA) approval, and the unmet clinical need remains pressing. Natural products are considered a promising option for this chronic and multifactorial disease due to their favorable safety profile and multi‐target effects. However, a narrative review of intervention strategies at various levels—from traditional Chinese medicine (TCM) formulas and plant extracts to natural compounds—is still lacking. We searched for publications from the past 4 years using PubMed, Web of Science, EMBASE, the Cochrane Library, and Scopus. This narrative review highlights the key role of NLRP3 inflammasome–related signaling pathways in the development of AS and evaluates the evidence for natural products targeting these pathways. Given the limitations of the available evidence, large‐scale, high‐quality randomized controlled trials are needed to establish clinical efficacy and safety.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
ORCID profiles: Haizhen Guo
Funding
- The Science & Technology Development Fund of Tianjin Education Commission for Higher Education
Cite
APA
Guo, H., Qian, S., Lu, Y., Zhao, Y., Su, Y., Song, Z., & Zhang, W. (2026). Targeting the NLRP3 Inflammasome in Atherosclerosis: Advances in Anti‐Inflammatory Therapies With Bioactive Natural Products. Phytotherapy Research, 40(5), 2758-2789. https://doi.org/10.1002/ptr.70260
Vancouver
Guo H, Qian S, Lu Y, Zhao Y, Su Y, Song Z, et al. Targeting the NLRP3 Inflammasome in Atherosclerosis: Advances in Anti‐Inflammatory Therapies With Bioactive Natural Products. Phytotherapy Research. 2026;40(5):2758-2789. doi:10.1002/ptr.70260
BibTeX
@article{Guo2026,
author = {Guo, Haizhen and Qian, Shule and Lu, Yu and Zhao, Yuke and Su, Yuqing and Song, Zhijie and Zhang, Wenyu},
title = {Targeting the NLRP3 Inflammasome in Atherosclerosis: Advances in Anti‐Inflammatory Therapies With Bioactive Natural Products},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {5},
pages = {2758--2789},
doi = {10.1002/ptr.70260}
}
EUVIMED